Test Price
2,800 AED✅ Home Collection Available
JAK2 Gene Mutation NGS Test for Acute Myelogenous Leukemia (AML) in UAE | 2800 AED | 2026 DHA Guidelines
تحليل طفرة جين JAK2 لسرطان الدم النقوي الحاد (AML) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Certified Processing.
دقة تشخيصية 99.9% من خلال معالجة معتمدة ISO.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy.
خدمة سحب الدم المنزلي المدفوعة عبر سلسلة تبريد معتمدة ISO وفريق تمريض متنقل VIP.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
استشارة سريرية هاتفية بعد الفحص لتفسير النتائج.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
التحقق من تغطية التأمين مباشرة عبر واتساب.
Test Overview & Clinical Utility
This Next-Generation Sequencing (NGS) analysis detects all coding-region mutations in the JAK2 gene associated with Acute Myelogenous Leukemia (AML), guiding precise subtyping and targeted therapy selection. يحدد فحص التسلسل الجيني من الجيل التالي (NGS) جميع الطفرات في الجين JAK2 المرتبطة بسرطان الدم النقوي الحاد، مما يوجه التشخيص الدقيق واختيار العلاج الموجه.
| Feature | Our JAK2 Full Gene NGS | Closest Alternative (JAK2 V617F PCR) |
|---|---|---|
| Methodology | Next-Generation Sequencing (Illumina) | Allele-Specific PCR / Sanger |
| Coverage | All coding exons (1–25) + splice sites | Exon 14 V617F mutation only |
| Analytical Sensitivity | ≤1% variant allele frequency | 5–10% (risk of false-negative) |
| Turnaround Time | 3–4 Weeks | 1–2 Weeks |
| Clinical Applications | AML subtype confirmation, JAK inhibitor eligibility, prognosis stratification | Primary diagnosis of polycythemia vera / essential thrombocythemia |
Physician Insight & Safety Protocol
“A JAK2 mutation result can be transformative for your leukemia management plan. I urge each patient to view this genetic information as a piece of a larger puzzle that must be interpreted alongside blood counts, bone marrow biopsy, and clinical symptoms. Never stop or adjust any prescribed medication without first consulting your hematologist.”
– Dr. Prabhakar Reddy, Consultant Oncologist, DHA License 61713011
Safety Notice & Exclusion Criteria
- Do not discontinue prescribed medications without direct physician consultation.
- Recent blood transfusion (within 2 weeks) may affect DNA yield; reschedule accordingly.
- Active chemotherapy or radiation may compromise sample quality; discuss optimal timing with your oncologist.
- Absolute contraindication: none for venipuncture; relative contraindication: severe anemia requiring immediate transfusion.
Emergency Red Flags
Seek immediate medical attention if you experience sudden bone pain, unexplained bleeding, high fever, or severe fatigue – these may indicate disease progression. Contact your physician or local ER.
Frequently Asked Questions
1. What is the purpose of JAK2 mutation testing in AML?
ما الغرض من فحص طفرة JAK2 في سرطان الدم النقوي الحاد؟
This NGS test identifies JAK2 gene mutations to confirm AML subtype, guide targeted therapy, and assess prognosis. A positive JAK2 result may indicate eligibility for JAK inhibitors like ruxolitinib, often combined with standard chemotherapy. It also helps in distinguishing de novo AML from myeloproliferative neoplasms that progress to leukemia.
2. How should I prepare for the?
كيف أستعد للفحص؟
You require a genetic counseling session to chart your family history and understand implications. The actual sample collection requires a standard blood draw (or buccal swab if using FTA card), with no fasting necessary. Bring a list of current medications and prior medical records to the counseling session. If extracting DNA from saliva or buccal cells, avoid eating, drinking, smoking 30 minutes before collection.
3. What does a positive JAK2 mutation result mean?
ماذا تعني النتيجة الإيجابية لطفرة JAK2؟
A JAK2 mutation indicates a myeloid neoplasm that may benefit from JAK inhibitor therapy, but clinical correlation is essential. The exact variant (e.g., V617F, exon 12, or other rare mutations) will be reported with its significance. Your oncologist will integrate this with bone marrow blast count and cytogenetics to finalize the AML diagnosis and treatment plan. A negative result does not rule out AML – other genetic drivers may be present.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians